Bank of America Securities analyst Tazeen Ahmad has maintained their bullish stance on KALV stock, giving a Buy rating on June 3.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Tazeen Ahmad has given his Buy rating due to a combination of factors related to KalVista Pharmaceuticals’ promising developments in the treatment of acute hereditary angioedema (HAE). The company’s oral therapy, sebetralstat, is nearing a critical regulatory decision, with the potential to become the first oral treatment for acute HAE, offering a more convenient alternative to current injectable options. This innovation addresses a significant unmet need in the HAE treatment landscape by providing faster symptom relief and ease of use.
KalVista is well-prepared for the potential launch of sebetralstat, with strong commercial readiness and strategic programs to support its uptake post-approval. The company has engaged extensively with healthcare providers, payors, and the patient community, receiving positive feedback on the pricing strategy. These factors, combined with a favorable safety profile and the potential to capture a significant market share, underpin the Buy rating and the price objective of $22.
In another report released on June 3, JonesTrading also reiterated a Buy rating on the stock with a $30.00 price target.
KALV’s price has also changed dramatically for the past six months – from $8.745 to $13.090, which is a 49.69% increase.